Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA OK's Medtronic's high-energy HF (heart failure) device:

This article was originally published in Clinica

Executive Summary

Medtronic has gained US approval to sell the latest product in its line of devices for treating heart failure (HF). The InSync Maximo cardiac resynchronisation therapy defibrillator (CRT-D) stops lethally fast heart rhythms using a combination of high-output defibrillation energy (35 joules) and what the firm claims is the industry's fastest charge times - ie the number of seconds between the time the device detects an abnormally fast rhythm and the moment it is ready to deliver defibrillation therapy.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT058935

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel